Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing"

Affiliations

¹ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
² Medical Statistics Core Facility, IDIBAPS, Hospital Clinic Barcelona, Spain; Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERehd, Barcelona, Spain.
⁴ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address: jbruix@clinic.ub.es.

Comment

Maria Reig et al. J Hepatol. 2016 Oct.

. 2016 Oct;65(4):864-865.

doi: 10.1016/j.jhep.2016.05.036. Epub 2016 May 30.

¹ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
² Medical Statistics Core Facility, IDIBAPS, Hospital Clinic Barcelona, Spain; Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERehd, Barcelona, Spain.
⁴ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address: jbruix@clinic.ub.es.

No abstract available

Comment on

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Reig M, et al. J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13. J Hepatol. 2016. PMID: 27084592
Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.
Cammà C, Cabibbo G, Craxì A. Cammà C, et al. J Hepatol. 2016 Oct;65(4):861-862. doi: 10.1016/j.jhep.2016.04.033. Epub 2016 May 30. J Hepatol. 2016. PMID: 27255578 No abstract available.
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment.
Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Torres HA, et al. J Hepatol. 2016 Oct;65(4):862-864. doi: 10.1016/j.jhep.2016.05.034. Epub 2016 May 30. J Hepatol. 2016. PMID: 27255582 No abstract available.